These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18220768)

  • 1. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases.
    Sipos W; Pietschmann P; Rauner M
    Curr Med Chem; 2008; 15(2):127-36. PubMed ID: 18220768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies.
    Leibbrandt A; Penninger JM
    Adv Exp Med Biol; 2009; 649():100-13. PubMed ID: 19731623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
    Takayanagi H; Ogasawara K; Hida S; Chiba T; Murata S; Sato K; Takaoka A; Yokochi T; Oda H; Tanaka K; Nakamura K; Taniguchi T
    Nature; 2000 Nov; 408(6812):600-5. PubMed ID: 11117749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RANKL-RANK Axis: A Bone to Thymus Round Trip.
    Sobacchi C; Menale C; Villa A
    Front Immunol; 2019; 10():629. PubMed ID: 30984193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
    Chen T; Feng X
    Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S
    Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoblast Role in Rheumatic Diseases.
    Corrado A; Maruotti N; Cantatore FP
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28617323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.
    Shen Y; Jiang T; Wang R; He S; Guo M; Zuo J; He D
    BMC Complement Altern Med; 2015 Mar; 15():77. PubMed ID: 25887296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANK/RANKL: regulators of immune responses and bone physiology.
    Leibbrandt A; Penninger JM
    Ann N Y Acad Sci; 2008 Nov; 1143():123-50. PubMed ID: 19076348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
    Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
    Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone disease in multiple myeloma.
    Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
    Med Oncol; 2006; 23(4):431-41. PubMed ID: 17303901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss.
    Kleyer A; Scholtysek C; Bottesch E; Hillienhof U; Beyer C; Distler JH; Tuckermann JP; Schett G; Krönke G
    J Bone Miner Res; 2012 Dec; 27(12):2442-51. PubMed ID: 22806960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines.
    Naidu VG; Dinesh Babu KR; Thwin MM; Satish RL; Kumar PV; Gopalakrishnakone P
    Chem Biol Interact; 2013 Apr; 203(2):467-79. PubMed ID: 23333834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
    Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoimmunology in orthodontic tooth movement.
    Jiang C; Li Z; Quan H; Xiao L; Zhao J; Jiang C; Wang Y; Liu J; Gou Y; An S; Huang Y; Yu W; Zhang Y; He W; Yi Y; Chen Y; Wang J
    Oral Dis; 2015 Sep; 21(6):694-704. PubMed ID: 25040955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANKL-RANK signaling in osteoclastogenesis and bone disease.
    Wada T; Nakashima T; Hiroshi N; Penninger JM
    Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model.
    Ohtsuji M; Lin Q; Nishikawa K; Ohtsuji N; Okazaki H; Tsurui H; Amano H; Shirai T; Nishimoto N; Nishimura H; Hirose S
    Mod Rheumatol; 2015 Mar; 25(2):270-7. PubMed ID: 25159156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.